Wegovy is a registered trademark of Novo Nordisk A/S. Medicaid coverage may be available in some circumstances, but there is no single answer that applies to every state, plan, patient, or prescribed use.
Important safety information: Wegovy has a boxed warning about the risk of thyroid C-cell tumors. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Serious risks include pancreatitis, gallbladder problems, low blood sugar, acute kidney injury, severe gastrointestinal reactions, serious allergic reactions, diabetic retinopathy complications, and increased heart rate. Review the complete official Wegovy Prescribing Information and Medication Guide with a licensed clinician.
This page is general information, not medical advice. Talk to a licensed clinician about your situation.
Why Medicaid answers differ by state
Medicaid is jointly funded by federal and state governments, but each state administers its own program within federal rules. The federal Medicaid prescription drug overview explains that outpatient prescription coverage is an optional benefit, although every state currently provides it to categorically eligible people and most other enrollees.
That does not mean every outpatient drug is covered for every use. A state may use a preferred drug list, prior authorization, clinical criteria, quantity limits, and pharmacy network rules. A Medicaid managed care plan may also administer the benefit, so the card in a person's wallet matters.
Coverage can change during the year. A search result, pharmacy estimate, or another patient's experience is not the source of truth for a current benefit. The state Medicaid agency, the member's managed care plan, and the formal claim or authorization decision are the reliable sources.
The prescribed use matters
Wegovy has more than one labeled use. Its FDA prescribing information includes long-term weight management for certain adults and pediatric patients, cardiovascular risk reduction for certain adults with established cardiovascular disease and overweight or obesity, and another indication described in the current label.
Medicaid rules may treat these uses differently. Federal Medicaid guidance has explained that coverage obligations can depend on the FDA-approved indication and other drug-rebate rules. A state may separately restrict drugs when used for weight loss. That is why asking only whether the drug appears on a list can produce an incomplete answer.
The prescriber must document the actual clinical reason for treatment. A patient should not select a diagnosis or request different wording simply to affect coverage. The medical record, prescription, and authorization request must be accurate.
How to check your current benefit
Start with the member services number on the Medicaid or managed care card. Ask for the pharmacy benefit department and use the full prescription name. Then ask:
- Is the prescribed use covered under my current benefit?
- Is Wegovy on the current preferred drug list or formulary?
- Does it require prior authorization, step therapy, or another review?
- Which pharmacies can fill it under this plan?
- What cost sharing applies if the request is approved?
Request the name or location of the written coverage criteria. Record the date of the call and any reference number. If the plan says an authorization is required, ask which form and supporting records the prescriber must submit.
Do not treat a favorable phone answer as guaranteed payment. The plan makes its decision after it receives and evaluates the required information. The pharmacy can confirm the processed amount only after it submits the claim.
Prior authorization and denials
Prior authorization is a coverage review, not a prescription. It may require the clinician to confirm the diagnosis, medical history, previous care, or other facts listed in the plan's current criteria. Requirements vary, and submitting a request does not assure approval.
If a request is denied, read the written notice. It should identify the reason and explain available appeal or fair-hearing rights. A denial based on missing information is different from a denial based on an excluded use or unmet clinical criteria.
Contact the plan for benefit questions and the clinical team for medical-record questions. Deadlines may apply. The patient and clinician should use truthful records and follow the instructions in the notice rather than relying on general advice from a price website.
Medicaid and Medicare are not the same
Some people qualify for both Medicaid and Medicare. For a dual-eligible member, Medicare Part D commonly handles outpatient prescription coverage first, while Medicaid may help with certain costs or benefits under applicable rules. The exact coordination depends on the person's coverage.
CMS also operates a Medicare GLP-1 Bridge beginning July 1, 2026, for certain eligible Part D beneficiaries and specified weight-management uses. That is a Medicare initiative, not a general Medicaid coverage rule. A person should not assume eligibility based on having a Medicaid card.
If both programs appear on your coverage documents, call the Part D plan and the state or managed Medicaid plan. Ask which benefit is primary for the prescription and which pharmacy network applies.
Body Good coverage support and fees
Body Good can assist with a benefits check and requested prior authorization paperwork. This is coverage support. Approval and payment are determined by the Medicaid agency or managed care plan, not by Body Good.
Body Good's prices are service fees for the program described during intake. They are not the price of medication and are not a quote for any individual. Eligibility is determined by a clinician. The medication cost is separate and is not included in a Body Good service fee.
This website is an informational and pricing overview. It does not take payment, collect protected health information, or run an intake form. Intake and checkout occur on joinbodygood.com.
Frequently asked questions
Does every state Medicaid program cover Wegovy for weight management?
No uniform national answer applies. State policies, managed care rules, prescribed use, and current clinical criteria can differ. Check the member's current plan documents and request a plan-specific determination.
What should I do if Medicaid denies the request?
Read the written denial, identify the stated reason, and follow its appeal instructions and deadlines. Ask the plan what information is missing and speak with the clinician about accurate supporting records.
Can Body Good check my Medicaid benefit?
Body Good may provide coverage support, but it cannot promise approval or payment. Start the secure clinical intake to provide information for clinical review.
Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Body Good is not affiliated with, endorsed by, sponsored by, or authorized by Eli Lilly and Company or Novo Nordisk A/S. All trademarks are the property of their respective owners.